The CDTI Innovation invests, together with ASABYS, MEDLUMICS, S.L., company dedicated to the development of medical devices based on high technology

MedLumicsit is a company of medical devices which develops AblaView ®, the first ablation catheter in real time guided Optically for the treatment of atrial fibrillation (FA).

The atrial fibrillation is the most common type of cardiac irregular heart rate and it is estimated that currently affects 43 million people around the world. The recurrence of fmd remains very high, and more than 20 per cent of patients are subject to a new circumcision in the first year since the initial treatment. Innovations in this area in the past 20 years have been ineffective in reducing the rate of complications resulting from the thermal energy or mitigation of recurrencias and repetition rates derived from the treatment procedures incomplete.

AblaView, a system of hybrid catheter guided Optically, is a pioneering system in the world, incorporates the Reflectometría coherence Lens (OCR) to provide the electrofisiólogo (EF) a visual guide that allows you to assess first-hand and in real time the progression of the injury.

Current technologies requires the electrofisiólogo based on indirect markers that provide indirect information outside of heart tissue that it was trying to guide the proceedings. The second hand information leads to an incomplete treatment, which triggers the recurrence of the FA, increasing the costs by the repetition of treatment and, more seriously, the over-treatment, causing life-threatening complications, such as the disorder and fistula -perforación of plugging problems.

The dual energy AblaView is a real game changer "". The OCR technology directly measuring the Optical properties of the organization of the tissues, called birrefringencia, as it applies the ablation therapy with energy radiofrequency (RF) or electroporation irreversible (IRE). The measurement of Optical birrefringencia provides information to guide and direct confirms the stability of the contact of the tip of the catheter with fabric, the depth of the progression of the injury and durability of the injury with precision and unprecedented specificity. The guide In real time allows for the first time the electrofisiólogo monitoring the implementation of energy to avoid complications thermally accurately predict the full treatment of patients to improve security and reduce the recurrence of the FA. Commercially, double energy extends the penetration of aurícula AblaView from to the market billionaire and untapped the ventricular tachycardia episode.

Asabys Partners

Asabys Partnersit is a venture capital firm specialized in health, founded in 2018 by Josep Ll. Sanfeliu and clear, shared by Campàs Alantra and with the support of the Banco Sabadell anchor. investor Almost €225 million in assets under management and 16 investees (+ 1 exit), Asabys invests in innovative companies disruptive and addressing unmet medical needs in the areas of biotechnology and pharmaceuticals and health technology investment in this company has been made since their vehicles Sabadell Asabys Health Innovation Investments SCR, SA, and Top Up Asabys FCR. www.asabys.com. Fund,

CDTI Innovation

The CDTI innovation is the agency of the ministry of science, innovation and universities that supports innovation based on knowledge, advice and providing public funding for innovation through subsidies or aid partly refundable for innovation and managing public procurement, pre-commercial.

Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI, through Innvierte, has committed over 384 M €in 20 investment vehicles that have invested in more than 250 businesses, and through its joint investment line directly committed an amount of more than 342 M €in at least 135 companies.

The CDTI Innovation also facilitates the internationalization of business projects of r & D and innovation of spanish companies and entities and manages the participation of spanish companies in international r & D, Horizon and Eureka, Europe and in industries of science and space.

The centre for technological development and innovation, E.P.E. (CDTI) is a public entity under the ministry of Science, innovation and universities.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

This content is copyright © 2024 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).